Mayne Pharma to present at the 20th Bioshares Summit
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA TO PRESENT AT THE 20TH
BIOSHARES
SUMMIT
3 August 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the
Company)(ASX: MYX), today announces an upcoming presentation to the 20th
Bioshares Summit
in Queenstown,New Zealand by the CEO Mr Aaron Gray at 9.40am (NZ time) on Thursday 6 August
2026.
The annual Bioshares Summit features 38 speakers from ASX-listed and private healthcare and
biotechnology companies over two days, including facilitated investor meetings.
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
Authorised for release to the ASX by the Chair.
Email Alerts
To register for an email alert service to receive Mayne Pharma announcements released to the
Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investor-
relations/email-alerts/
Follow us on LinkedIn
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-
year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com.
Share your feedback
Discover